Many Kite Pharma, Inc.(KITE) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Kite Pharma Inc was Initiated by Wedbush on Feb 2, 2017 to Neutral, Price Target of the shares are set at $46.Kite Pharma Inc was Initiated by ROTH Capital on Jan 4, 2017 to Buy, Price Target of the shares are set at $68.Kite Pharma Inc was Initiated by H.C. Wainwright on Nov 21, 2016 to Buy, Price Target of the shares are set at $78.
Company has reported several Insider transactions to the SEC, on Feb 6, 2017, Jeffrey Wiezorek (SVP Clinical Development) sold 1,500 shares at 51.21 per share price.On Feb 1, 2017, Cynthia M Butitta (Chief Operating Officer) sold 10,000 shares at 50.56 per share price.On Dec 22, 2016, Shawn Tomasello (Chief Commercial Officer) sold 4,901 shares at 50.86 per share price.
Kite Pharma Inc Last issued its quarterly earnings results on Nov 9, 2016. The company reported $-1.10 EPS for the quarter, missing the analyst consensus estimate by $ -0.02. Analyst had a consensus of $-1.08. The company had revenue of $7.30 million for the quarter, compared to analysts expectations of $4.90 million. The companys revenue was up 43.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.38 EPS.
Kite Pharma, Inc. (NASDAQ:KITE) has received a short term rating of sell from experts at Zacks with a rank of 4. The stock has been rated an average of 1.42 by 12 Brokerage Firm. 9 Wall Street Firms have rated the stock as a strong buys. 1 stock experts have also suggested a buy rating. 2 Brokerage Firms have advised hold.
Kite Pharma, Inc. (NASDAQ:KITE): The mean estimate for the short term price target for Kite Pharma, Inc. (NASDAQ:KITE) stands at $70.82 according to 11 Analysts. The higher price target estimate for the stock has been calculated at $80 while the lower price target estimate is at $46.
Kite Pharma, Inc. (NASDAQ:KITE) rose 1.06% or 0.57 points on Tuesday and made its way into the gainers of the day. After trading began at $54.12 the stock was seen hitting $54.6 as a peak level and $53.81 as the lowest level. The stock ended up at $54.54. The daily volume was measured at 603,888 shares. The 52-week high of the share price is $64.3 and the 52-week low is $39.82. The company has a market cap of $2,720 million.
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of cancer immunotherapy products. The Company is developing a pipeline of eACT-based product candidates for the treatment of solid and hematological malignancies. Kite Pharma, Inc. is headquartered in Santa Monica, California.